aTyr Pharma Inc (NASDAQ:LIFE) has been given a consensus rating of “Hold” by the six research firms that are covering the stock, Marketbeat reports. Four analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $1.01.

Several brokerages recently issued reports on LIFE. ValuEngine downgraded shares of aTyr Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Zacks Investment Research cut shares of aTyr Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, January 16th. Finally, William Blair restated a “market perform” rating on shares of aTyr Pharma in a research report on Tuesday, March 26th.

Shares of LIFE stock opened at $0.47 on Thursday. aTyr Pharma has a 12-month low of $0.38 and a 12-month high of $1.37. The stock has a market cap of $17.14 million, a P/E ratio of -0.41 and a beta of 2.51. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.25.

aTyr Pharma (NASDAQ:LIFE) last announced its quarterly earnings results on Monday, May 13th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.05.

A hedge fund recently raised its stake in aTyr Pharma stock. Renaissance Technologies LLC raised its stake in aTyr Pharma Inc (NASDAQ:LIFE) by 107.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,107,025 shares of the biotechnology company’s stock after acquiring an additional 573,164 shares during the quarter. Renaissance Technologies LLC owned about 3.71% of aTyr Pharma worth $899,000 as of its most recent filing with the Securities and Exchange Commission. 29.20% of the stock is owned by institutional investors and hedge funds.

About aTyr Pharma

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for treating patients with interstitial lung diseases (ILDs), such as pulmonary sarcoidosis; and in Phase 1 clinical trial to treat chronic hypersensitivity pneumonitis and connective tissue disease ILD.

Recommended Story: Balanced Fund

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with's FREE daily email newsletter.